LNTH Lantheus Holdings, Inc.
In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 1521036 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.4%
TTM net income YoY61.0%
TTM EPS YoY66.8%
Revenue 3-yr CAGR9.0%
Net income 3-yr CAGR37.4%
Margins
Gross margin61.3%
Operating margin18.6%
Net margin17.3%
FCF margin25.2%
EBITDA margin24.4%
Returns
ROE21.8%
ROA11.4%
ROIC (approx.)18.0%
Asset turnover0.66x
Leverage & solvency
Liabilities / assets44.8%
Debt / equity0.42x
Current ratio3.25x
Interest coverage14.70x
Cash quality & payout
Operating cash flow / net income1.52x
Accruals ratio-5.9%
Payout ratio—
Capex / revenue1.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.54B | $1.53B |
| Cost of revenue | $599.66M | $545.62M |
| Gross profit | $941.95M | $988.29M |
| R&D expense | $177.31M | $168.10M |
| SG&A expense | $275.12M | $193.69M |
| Operating income | $310.83M | $456.98M |
| Interest expense | $19.75M | $19.67M |
| Pretax income | $313.79M | $430.98M |
| Income tax | $80.23M | $118.53M |
| Net income | $233.56M | $312.44M |
| EBITDA | $380.93M | $521.60M |
| EPS (basic) | 3.46 | 4.52 |
| EPS (diluted) | 3.41 | 4.36 |
| Weighted avg. shares (diluted) | 68.44M | 71.65M |
| Balance sheet | ||
| Cash & equivalents | $359.12M | $914.49M |
| Receivables | $358.64M | $321.26M |
| Inventory | $64.67M | $68.03M |
| Current assets | $899.96M | $1.33B |
| PP&E, net | $163.69M | $176.80M |
| Goodwill | $239.52M | $61.19M |
| Intangibles | $722.78M | $161.76M |
| Total assets | $2.23B | $1.98B |
| Current liabilities | $333.42M | $240.53M |
| Short-term debt | $738,000 | $974,000 |
| Long-term debt | $568.68M | $565.28M |
| Total debt | $569.42M | $566.25M |
| Total liabilities | $1.14B | $892.33M |
| Shareholders' equity | $1.09B | $1.09B |
| Net debt | $210.29M | -$348.23M |
| Shares outstanding | 64.59M | 68.45M |
| Cash flow statement | ||
| Operating cash flow | $390.14M | $544.75M |
| Capital expenditure | $36.09M | $51.62M |
| Free cash flow | $354.05M | $493.12M |
| Investing cash flow | -$627.17M | -$226.01M |
| Financing cash flow | -$316.58M | -$118.54M |
| Depreciation & amortization | $70.10M | $64.62M |
| Stock-based compensation | $85.56M | $76.39M |
| Share buybacks | $300.02M | $100.00M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.